All In Biotech

Drug Trial Radar · NCT00129259

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Phase II Multiple-Dose Treatment of New Onset Type 1 Diabetes Mellitus With Anti-CD3 mAb

Last checked: Nov 20, 2026Latest source record: May 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

83

Actual

Start

Sep 2005

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Sponsor type
NIH
Collaborators
Immune Tolerance Network (ITN)
First posted
Aug 11, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 8 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 \[Ala-Ala\],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection. The purpose of this study is determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • Anti-CD3 mAbBiological

    Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval

  • Diabetes Standard of Care TreatmentOther

    Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.

  • Iron supplementationDietary supplement

    Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT)Time frame: Baseline (Pre-treatment), Month 24

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The Diabetes Center at UCSF

    San Francisco, California

  • Barbara Davis Center for Childhood Diabetes

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • Medical College of Georgia

    Augusta, Georgia

  • Dept. of Medicine, Division of Endocrinology and the Naomi Berrie Diabetes Center/Columbia University

    New York, New York

  • Benaroya Research Institute

    Seattle, Washington

  • Pacific Northwest Research Institute/University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.